expresspharmaAugust 15, 2019
Tag: prices , increase , knee implant
The ceiling price of orthopaedic knee implants to be monitored such that the price increase of knee implants does not increase beyond 10 per cent in a given year.
The NPPA has notified the ceiling price of orthopaedic knee implants by invoking extraordinary powers in public interest under Para 19 of Drugs Prices Control Order (DPCO) 2013, for a period of one year. Subsequently, vide notification dated 13th August, 2018, the applicability of ceiling prices fixed for orthopaedic knee implants was extended for another one year, up to 15th August, 2019.
Accordingly, the cost of knee implants was reduced significantly, upto 69 per cent, resulting in a notional saving of Rs 1,500 crore per annum to the consumers.
The NPPA, in its meeting held on 8th August, 2019, reviewed the matter. It was noted that there has been an increased access due to knee implants becoming affordable. As per the data submitted by manufacturers and importers, an increase of 30 per cent in the sales of knee implants has been reported during the period of July 2018 to June 2019.
The knee implant is a non-scheduled medical device/drug for which DPCO, 2013 allows an annual increase up to 10 per cent of MRP. However, this was not permitted in 2018.
Though the industry has requested for a 20 per cent (10 per cent for the year 2018 and 10 per cent for the year 2019) increase in the price of knee implants, it was decided to further monitor the price increase of knee implants as per para 20 of the DPCO, 2013 that restricts price increase beyond 10 per cent in a given year. This shall be subject to a review after one year.
Sharing his views on the move, Medical Technology Association of India’s (MTaI) Chairman and Director General Pavan Choudary said, "We were seeking a 20 per cent increase in the selling price of knee implants to make up for two years of price control combined with continuing pressures of rupee devaluation and inflation. Having said that, it is reassuring that the government has begun to acknowledge the financial pressures on medical device companies and has decided to give a partial relief by letting companies increase the price by 10 per cent in next one year, as per Para 20 of DPCO, 2013. As we move ahead, we will continue to engage with the government for a long-term solution"– MTaI Chairman, Mr. Pavan Choudary.
By EP News Bureau
-----------------------------------------------------------------------
Editor's Note:
If you have any suggestion to the content,
please email: Julia.Zhang@ubmsinoexpo.com
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: